logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Akero Therapeutics: Two Financing Transactions with Pfizer and Hercules Capital

Akero Therapeutics Financing Transactions Akero Therapeutics ( AKRO ) is one of the selected firms for the Prohost Portfolio . The firm is clinical-stage and develops treatments for metabolic diseases marked by high unmet medical need. The firm’s focus is...

Read More

June 27, 2022

0

Pivotal Data About Efficacy and Tolerability of Arcturus Therapeutics’ COVID-19 Vaccine Published in Nature Communications  

Arcturus Therapeutics COVID-19 Vaccine Published CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics ( ARCT ) announced that Journal Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT-154, a novel self-amplifying (sa-mRNA)...

Read More

May 22, 2024

0

Exelixis Announces Q2 2024 Financial Results and Provides Corporate Update  

Exelixis Q2 Results and Corporate Update Yesterday, Aug. 6, 2024, Exelixis, ( EXEL ) reported financial results for the second quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial,...

Read More

August 7, 2024

0

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting 

Moderna to Host Investor Event Via Webcast Moderna, Inc. ( MRNA ) announced that three abstracts on mRNA-4157 ( V940 ), an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2024 American Society of Clinical Oncology...

Read More

May 23, 2024

0

Celldex Therapeutics: More Promising Results in Treating Chronic Spontaneous Urticaria Refractory to Antihistamines

Celldex Therapeutics Interim Trial Data for Barzolvolimab Interim data from Celldex Therapeutics ( CLDX ) Phase 1b clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria ( CSU ) refractory to antihistamines demonstrate meaningful symptom improvements....

Read More

July 2, 2022

0

Cytokinetics Reports Management Update and Q2 2024 Financial Results

Cytokinetics Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing, and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The company is developing small-molecule drug candidates specifically...

Read More

August 12, 2024

0

FDA Lifted the Clinical Hold on Vertex Product VX-880 for Type 1 Diabetes

Vertex Pharmaceuticals VX-880 for Type 1 Diabetes Vertex Pharmaceuticals ( VRTX ) announced that the FDA has lifted the clinical hold placed on the Phase 1/2 clinical trial of VX-880. VX-880 is an investigational allogeneic stem cell-derived, fully differentiated pancreatic...

Read More

July 6, 2022

0

Ionis Pharmaceuticals Presented Positive Results from Two Late Studies of investigational Product Donidalorsen

Ionis Parmaceuticals Treating Hereditary Angioedema On May 31, 2024, Ionis Pharmaceuticals ( IONS ) announced positive results from two Phase 3 OASIS-HAE and OASIS plus studies of the firm’s Donidalorsen in patients with hereditary angioedema ( HAE ). Donidalorsen demonstrating...

Read More

June 3, 2024

0

What About Agenus?

Answering Questions and Our Opinion About Agenus We believe that Agenus' ( AGEN ) frozen stock price for several years has and will continue to move up based on the recent news regarding the firm's promising oncology products. That's in addition...

Read More

June 5, 2024

0

Gilead Sciences and Arcus Biosciences: Treating Gastrointestinal Cancers

Gilead Sciences and Arcus Biosciences in the NEWS Gilead Sciences ( GILD ) and Arcus Biosciences ( RCUS ) announced longer-term efficacy and safety results from Arm A1 of Phase 2 EDGE-Gastric study. The updated data demonstrate consistent objective response...

Read More

June 6, 2024

0

  • Previous
  • 1
  • 2
  • ...
  • 62
  • 63
  • 64
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy